Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review

Occult breast cancer (OBC) signifies a rare subset of breast cancers, accounting for only 0.3 to 1% of all breast cancers. Diagnosing cancer of unknown primary requires a comprehensive approach, including histological examination, immunohistochemistry, multidisciplinary team assessments, and special...

Full description

Saved in:
Bibliographic Details
Main Authors: Ketan Makwana, Shaunak Valame
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd.
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1787710
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Occult breast cancer (OBC) signifies a rare subset of breast cancers, accounting for only 0.3 to 1% of all breast cancers. Diagnosing cancer of unknown primary requires a comprehensive approach, including histological examination, immunohistochemistry, multidisciplinary team assessments, and specialized therapy. We present the case of a postmenopausal woman diagnosed with OBC with diffuse carcinomatosis of the bone marrow (DCBM), which was hormone receptor positive and Her2neu negative. Treatment with aromatase inhibitor and the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib yielded significant clinical improvement. The full potential of this therapy warrants investigation in real-world studies.
ISSN:0971-5851
0975-2129